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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S47Methods: An oligonucleotide pull-down assay followed by isobaric
mass tag labeling and tandem mass spectrometry was used to isolate
and quantify the proteins binding to each rs143383 allele. Further trans-
acting factors were identiﬁed using TransFac, Promo 3.0 and TESS
prediction software databases, followed by electrophoretic mobility
shift assays (EMSAs). Candidate proteins were investigated further
using antibody supershifts, and their ability to modulate GDF5
expression assessed using RNA interference (RNAi). Luciferase reporter
assays were used to assess the impact of over-expressing candidate
proteins on the transcriptional activity of both rs143383 alleles. Chro-
matin Immunoprecipitation (ChIP) was used to conﬁrm the binding of
these factors to GDF5 in-vivo.
Results: Tandem mass spectrometry identiﬁed the transcriptional co-
activator p15 as binding more avidly to the T-allele of rs143383. Upon
p15 knockdown, overall GDF5 expression increased while the allelic
expression imbalance was attenuated. Furthermore, GDF5 was enriched
following ChIP with an anti-p15 antibody. By EMSA supershift, we
identiﬁed the more avid binding of transcription factors Sp1 and Sp3 to
the T-allele of rs143383. RNAi-mediated silencing of Sp1 and Sp3
signiﬁcantly increased the expression of GDF5, and modulated the AEI
observed. Furthermore, results from ChIP revealed that these two
factors bind GDF5 in-vivo.
Conclusions: p15, Sp1 and Sp3 bind to GDF5, this binding is modulated
by genotype at the rs143383 SNP, and these factors differentially
regulate the expression of GDF5. Now that these trans-acting factors
have been identiﬁed, they can serve as targets for modulating the OA
genetic deﬁcit mediated by rs143383.
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BRAIN FUNCTIONAL PROPERTIES PREDICT PLACEBO ANALGESIA IN
KNEE OSTEOARTHRITIS
A. Mansour, M. Baliki, T.J. Schnitzer, A.V. Apkarian. Northwestern Univ.,
Chicago, IL, USA
Purpose: Chronic pain is the primary complaint associated with OA,
serving as a predictor of physical dysfunction and muscular weakness.
As blinded, randomized placebo-controlled trials of therapeutic agents
in OA have repeatedly demonstrated a marked reduction in pain
response to placebo, studies of the brain response to placebo may
inform on brain properites of OA itself. Although mechanisms of
placebo response have been repeatedly studied in humans, we are the
ﬁrst to investigate its underlying brain properties in a clinical drug
study design. Here we investigate the possibility of identifying brain
properties that predispose different OA patients to placebo analgesia.
Methods: 20 patients meeting ACR criteria for knee OA were enrolled
into this single-blinded 4 week study. At baseline, patients were
instructed that they might be receiving either active drug or placebo;
however they all were given placebo for 2 weeks after which the treat-
mentwas stopped. At baseline and at the end of the 2weeks the patients
underwent an fMRI brain scan as well as a structural high resolution T1
brain scan; efﬁcacy reportswere collected on both occasions. Twoweeks
post cessation of medication patients were contacted again and same
efﬁcacy reports were recollected. The primary efﬁcacy measure was
Visual Analogue Scale 24 hour average pain rating. Secondary efﬁcacy
measures included WOMAC Index; Pain detect, Beck depression Index
(BDI), and Pain catastrophizing scale (PCS). In addition, 17 healthy age-
and gender-matched participants without knee pain were scanned at
baseline to serve as controls. For the analysis, the patient groups were
stratiﬁed as responders vs. non-responders to the placebo treatment
based on a decrease in visual analogue scale (VAS) pain rating equal to or
greater than 20% from baseline. Analysis was then conducted to deter-
mine differences in brain fMRI data between OA patients and controls as
well as betweenOAplacebo-responders vs.OAplacebo-non-responders.
Results: Of the 20 patients enrolled, 9 weremale and 11 female; mean
age was 57.8±6.6 years; mean duration of OA was 12.1±10.0 years.
3 patients discontinued prior to their week 2 visit; of the remainder,
8 responded to placebo (mean VAS dropped from 72.514.1 to
32.520.5, i.e., 56% decrease in VAS) whilst 9 did not show any signiﬁ-
cant change in reported pain (VAS changed from 66.78.2 to 704.7, i.e.,
a mean increase of 7%). OA vs controls: By comparing the general number
of connections across all brain regions between OA patients and controls
we conclude that the region constituted by the medial prefrontal cortex
(mpfc) and nucleus accumbans as well as the caudate is more connected
(p <0.05, corrected for multiplicity) in patients with OA than in controls.
OA-responders vs. OA-non responders: The secondary somatosensorycortex (S2) was generally more linked in the OA non-responders (p-
corrected < 0.05). In this group, the S2 region displayed signiﬁcantly
more connectivity with the ventro-lateral prefrontal cortex (vlpfc).
Moreover, the vlpfc showedmore connectivity (p-corrected< 0.05) with
the part of the brain network identiﬁed for OA, namely mpfc. Both S2
counts and vlpfc-mpfc connectivity predicted with very high accuracy
(AUC¼. 97 and .96, respectively) responders to placebo.
Conclusions: In this study, we have shown that brain information
sharing (functional connectivity) is different in OA in contrast to healthy
control subjects. Furthermore, analysis of activity of components of this
network predicts the response to placebo. Thus, placebo analgesia is
predictable from brain connectivity (information shared between brain
regions), prior to start of the placebo treatment trial. These results
suggest that distinct sub-groups of OA have distinct propensities for
placebo based on their brain states. The speciﬁc characteristics that
distinguish between these groups remains to be identiﬁed. The results
of the present study have important implications regarding OA, clinical
trials in OA, and for future designs of treatments for OA.
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PAIN PERCEPTION IN HAND OSTEOARTHRITIS: RELATION BETWEEN
CLINICAL NODES, RADIOLOGICAL SEVERITY, PAIN THRESHOLD AND
BRAIN PAIN PROCESSING
N.Sofat, J.Wajed, C. Smee,M.Hermansson, F.Howe, T.R. Barrick.StGeorge's,
Univ. of London, London, United Kingdom
Purpose: Hand osteoarthritis (OA) is a prevalent condition for which
treatments are based on analgesia and physical therapies. However, the
majority of patients continue to have symptoms of pain and reduced
function despite optimisation of current available treatments. We
hypothesised that inﬂammation in the hand joints due to osteoarthritis
enhances sensitivity and ﬁring of peripheral nociceptors, thereby
causing chronic pain. Our primary objective was to evaluate pain
perception in a cohort of participants with hand OA by assessing the
characteristics of nodal involvement, pain threshold in each hand joint
and radiological severity. Our secondary objective was to assess if
a standardised painful hand task showed evidence of brain pain pro-
cessing pathways using functional brain neuroimaging.
Methods: Participants with proximal and distal interphalangeal (PIP
and DIP) joint hand OA and non-OA controls were recruited. Clinical
parameters of local joint disease including clinical nodes, VAS (visual
analog score) for pain (0-100 mm scale), HAQ (health assessment
questionnaire), Kellgren-Lawrence scores for radiological severity in
each hand joint (30 regions per hand/subject using standard hand
radiographs and pain thresholds performed with algometers (Wagner
Instruments, USA) over each joint were assessed. Central brain pain
processing in all participants in the cohort was then evaluated using
a standardised ﬁnger ﬂexion-extension task. Subjects underwent
functional brain neuroimaging in a 1.5 Tesla MRI scanner (GE Health-
care) whilst they performed the ﬁnger ﬂexion-extension task to
measure central components of pain processing. Activation of central
pain processing pathways was then evaluated using group analyses
with FMRIB software (www.fmrib.ox.ac.uk/fsl).
Results: All hand OA participants reported pain despite 92% taking oral
analgesic drugs. The mean VAS in hand OA participants was 59.31 mm
+/-8.19 compared with 4.00 mm +/- 1.89 in the control group. Hand OA
participants also had HAQ scores 8-fold higher than controls indicating
high levels of functional impairment (p<0.05).Objectivemeasuresof pain
using algometers on 780 joints in total demonstrated lower pain thresh-
olds across not only DIP and PIP, but also CMC,MCP andwrist joints in the
OAgroupversus controls (p<0.0001). Therewasaglobal reduction inpain
threshold in thehandOAgroupdespite themain radiological changes and
nodal disease being found in the PIP and DIP joints respectively. Pain
threshold in the OA group did not vary signiﬁcantly with increasing
radiological severity. Functional brain MRI during the painful ﬁnger
ﬂexion-extension task demonstrated increased activation of the thal-
amus, cingulate gyrus, frontal and somatosensory cortex in the hand OA
group that was not observed in the control group (p<0.05). The activated
brain regions we observed are known brain pain processing regions.
Conclusions: Our data demonstrate that hand OA subjects are sensi-
tised to pain due to increased ﬁring of peripheral nociceptors. Hand OA
subjects demonstrate lower pain thresholds globally in their hands
compared with controls and have enhanced central sensitisation as
demonstrated by increased activation of central brain pain processing
pathways. Our ﬁndings also suggest that pain processing in OA is
